LadRx (STU:CX5) NonCurrent Deferred Liabilities: €0.00 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CX5 LadRx Corp STU:CX5
40 GF Score
Price €0.06
View Full Analysis

What is LadRx NonCurrent Deferred Liabilities?

LadRx STU:CX5 40 NonCurrent Deferred Liabilities is €0.00 Mil as of Mar. 2025. GuruFocus rates STU:CX5 with a GF Score™ of 40/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

LadRx's non-current deferred liabilities for the quarter that ended in Mar. 2025 was €0.00 Mil.

LadRx NonCurrent Deferred Liabilities Related Terms

LadRx NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for LadRx's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx NonCurrent Deferred Liabilities Chart

LadRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LadRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:CX5
40GF Score
LadRx Corp STU:CX5
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
LadRx (STU:CX5) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Mar. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on LadRx and its competitors.
Is LadRx's NonCurrent Deferred Liabilities too high?
LadRx's current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, LadRx has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does LadRx's NonCurrent Deferred Liabilities compare to VRTX and REGN?
LadRx's NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on LadRx and its competitors. LadRx's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (STU:CX5) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The current NonCurrent Deferred Liabilities is €0.00 Mil. LadRx's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For LadRx (STU:CX5), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
40GF Score

Get the complete analysis for STU:CX5

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price